Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the target of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 58,790 shares, a decline of 18.2% from the February 26th total of 71,837 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 15,085 shares, the short-interest ratio is presently 3.9 days.

Exicure Stock Performance

Shares of NASDAQ:XCUR opened at $4.41 on Monday. The firm has a market cap of $28.09 million, a price-to-earnings ratio of -5.73 and a beta of 4.13. The business has a 50-day simple moving average of $4.34 and a two-hundred day simple moving average of $4.67. Exicure has a fifty-two week low of $3.10 and a fifty-two week high of $14.11.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.14.

Analyst Ratings Changes

Several brokerages recently weighed in on XCUR. Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. Wall Street Zen raised Exicure to a “hold” rating in a research report on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.